← Comparing 2 hypotheses side-by-side
Add hypothesis:
— Select a hypothesis to add —
LPS-TLR4-NF-κB Signaling Cascade as Therapeutic Target (TLR4/NFKB1/NLRP3) — 7.20 Enteric Nervous System Dysfunction as Self-Reinforcing Patho (SNCA/GFAP/VIP/nNOS/CHAT) — 7.00 Vagus Nerve as Anatomical Highway for Prion-Like α-Syn Propa (SNCA/p-SNCA (Ser129)/GBA/LRRK2) — 6.00 SCFA Deficiency Disrupts Microglial Homeostasis and Promotes (HDAC3/GPR43 (FFAR2)/IL10/TREM2/OCLN) — 5.50 Metabolic Reprogramming to Reverse Senescence (SIRT1,PGC1A,NAMPT) — 1.00 Closed-loop transcranial focused ultrasound with 40Hz gamma (PVALB) — 1.00 TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen (TREM2) — 0.99 SASP Modulation Rather Than Cell Elimination (NFKB1,IL1B,BDNF) — 0.98 TREM2-Dependent Microglial Senescence Transition (TREM2) — 0.95 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.95 Closed-loop optogenetic targeting PV interneurons to restore (PVALB) — 0.94 PLCG2 Allosteric Modulation as a Precision Therapeutic for T (PLCG2) — 0.94 Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-00 (CSF p-tau217 (biomarker), lncRNA-0021, hUC-MSC exosomes) — 0.94 Multi-Biomarker Composite Index Surpassing Amyloid PET for T (COMPOSITE_BIOMARKER) — 0.93 Closed-loop focused ultrasound targeting CA1 PV interneurons (PVALB) — 0.93 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.92 CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microgli (CYP46A1) — 0.92 Autophagy-Senescence Axis Therapeutic Window (ATG7,BCL2,BCL2L1) — 0.92 Selective Acid Sphingomyelinase Modulation Therapy (SMPD1) — 0.92 HK2-Dependent Metabolic Checkpoint as the Gatekeeper of DAM (HK2) — 0.92 Palmitoylethanolamide-Based Endocannabinoid Therapy (PPARA) — 0.92 CYP46A1 Overexpression Gene Therapy (CYP46A1) — 0.92 Chromatin Remodeling-Mediated Nutrient Sensing Restoration (SMARCA4) — 0.91 Closed-loop transcranial focused ultrasound to restore hippo (CCK) — 0.91 SASP-Mediated Complement Cascade Amplification (C1Q/C3) — 0.91 TREM2-ASM Crosstalk in Microglial Lysosomal Senescence (SMPD1) — 0.91 TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene (TREM2) — 0.91 Nutrient-Sensing Epigenetic Circuit Reactivation (SIRT1) — 0.91 Closed-loop focused ultrasound targeting EC-II SST interneur (SST) — 0.90 CSF1R Inhibition-Mediated Microglial Replacement as a State (CSF1R) — 0.90
Add
|
× Branched-Chain Amino Acid × NAD+ Precursor Supplement
BCAT1/BCAT2 · metabolomics · -
Composite 0.400
Price $0.40
Evidence For 0
Evidence Against 0
Branched-Chain Amino Acid Transamination Inhibition to Modulate Neurotransmitter Homeostasis
PARP1, SIRT1/3, NAD+ · metabolomics · -
Composite 0.520
Price $0.52
Evidence For 0
Evidence Against 0
NAD+ Precursor Supplementation to Reverse Poly(ADP-ribose) Polymerase-Driven Metabolic Catastrophe
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
Unspecified Mechanism metabolomics
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary 2/11
dimensions won
Branched-Chain Amino Acid Transamination
11/11
dimensions won
NAD+ Precursor Supplementation to Revers
Radar Chart — 10 Dimensions
Score Breakdown
Dimension Branched-Chain Amino Acid Tran NAD+ Precursor Supplementation Mechanistic 0.500 0.650 Evidence 0.400 0.550 Novelty 0.450 0.450 Feasibility 0.450 0.750 Impact 0.450 0.600 Druggability 0.500 0.800 Safety 0.300 0.500 Competition 0.200 0.600 Data 0.400 0.650 Reproducible 0.350 0.550 KG Connect 0.500 0.500
Evidence Branched-Chain Amino Acid Transamination Inhibition to Modul No evidence citations yet
NAD+ Precursor Supplementation to Reverse Poly(ADP-ribose) P No evidence citations yet
Debate Excerpts Branched-Chain Amino Acid Transamination Inhibitio 4 rounds · quality: 0.50
Theorist
# Therapeutic Hypotheses: Metabolomic Signatures of Neurodegeneration
---
## Hypothesis 1: Restoration of Neuronal Ketone Body Utilization via MCT1 Upregulation
**Title:** MCT1 transporter upregu...
Skeptic
# Critical Evaluation of Metabolomic Hypotheses for Neurodegeneration
I'll provide a rigorous scientific critique of each hypothesis, identifying weaknesses, counter-evidence, alternative explanati...
Domain Expert
# Drug Discovery Assessment: Metabolomic Hypotheses for Neurodegeneration
## Executive Summary
All seven hypotheses face significant translational barriers. The metabolomics field provides genuine...
Synthesizer
```json
{
"ranked_hypotheses": [
{
"rank": 1,
"hypothesis_id": "H2",
"title": "NAD+ Precursor Supplementation to Reverse Poly(ADP-ribose) Polymerase-Driven Metabolic Catastro...
NAD+ Precursor Supplementation to Reverse Poly(ADP 4 rounds · quality: 0.50
Theorist
# Therapeutic Hypotheses: Metabolomic Signatures of Neurodegeneration
---
## Hypothesis 1: Restoration of Neuronal Ketone Body Utilization via MCT1 Upregulation
**Title:** MCT1 transporter upregu...
Skeptic
# Critical Evaluation of Metabolomic Hypotheses for Neurodegeneration
I'll provide a rigorous scientific critique of each hypothesis, identifying weaknesses, counter-evidence, alternative explanati...
Domain Expert
# Drug Discovery Assessment: Metabolomic Hypotheses for Neurodegeneration
## Executive Summary
All seven hypotheses face significant translational barriers. The metabolomics field provides genuine...
Synthesizer
```json
{
"ranked_hypotheses": [
{
"rank": 1,
"hypothesis_id": "H2",
"title": "NAD+ Precursor Supplementation to Reverse Poly(ADP-ribose) Polymerase-Driven Metabolic Catastro...
Price History Overlay
Knowledge Graph Comparison
Branched-Chain Amino Acid Transamination
5 edges
Top Node Types mechanism 3
gene 2
Top Relations implicates_in 5
NAD+ Precursor Supplementation to Revers
5 edges
Top Node Types mechanism 3
gene 2
Top Relations implicates_in 5